Page last updated: 2024-11-13
achn 490
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
plazomicin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 42613186 |
| CHEMBL ID | 1650559 |
| SCHEMBL ID | 11928040 |
| MeSH ID | M0548440 |
Synonyms (38)
| Synonym |
|---|
| CHEMBL1650559 |
| plazomicin |
| achn-490 |
| D10151 |
| plazomicin (usan) |
| 1154757-24-0 |
| SCHEMBL11928040 |
| (2s)-4-amino-n-((1r,2s,3s,4r,5s)-5-amino-4-((2-amino-2,3,4,6-tetradeoxy-6-((2- hydroxyethyl)amino)-alpha-d-glycero-hex-4-enopyranosyl)oxy)-2-((3-deoxy-4-c-methyl-3- (methylamino)-beta-l-arabinopyranosyl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide |
| d-streptamine, o-2-amino-2,3,4,6-tetradeoxy-6-((2-hydroxyethyl)amino)-alpha-d-glycero- hex-4-enopyranosyl-(1->4)-o-(3-deoxy-4-c-methyl-3-(methylamino)-beta-l- arabinopyranosyl-(1->6))-n(sup 1)-((2s)-4-amino-2-hydroxy-1-oxobutyl)-2-deoxy- |
| lyo9xz250j , |
| plazomicin [usan:inn] |
| unii-lyo9xz250j |
| achn490 |
| 6'-(hydroxylethyl)-1-(haba)-sisomicin |
| achn 490 |
| plazomicin [inn] |
| plazomicin [usan] |
| plazomicin [who-dd] |
| plazomicin [mi] |
| (2s)-4-amino-n-((1r,2s,3s,4r,5s)-5-amino-4-(((2s,3r)-3-amino-6-(((2-hydroxyethyl)amino)methyl)-3,4-dihydro-2h-pyran-2-yl)oxy)-2-((3-deoxy-4-c-methyl-3-(methylamino)-.beta.-l-arabinopyranosyl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide |
| d-streptamine, o-2-amino-2,3,4,6-tetradeoxy-6-[(2-hydroxyethyl)amino]-a-d-glycero-hex-4-enopyranosyl-(1?4)-o-[3-deoxy-4-c-methyl-3-(methylamino)-b-l-arabinopyranosyl-(1?6)]-n1-[(2s)-4-amino-2-hydroxy-1-oxobutyl]-2-deoxy- |
| DB12615 |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-{[(2s,3r)-3-amino-6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2h-pyran-2-y |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-{[(2s,3r)-3-amino-6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2h-pyran-2-yl]oxy}-2-{[3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| l]oxy}-2-{[3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| Q15426988 |
| gtpl10847 |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-[[(2s,3r)-3-amino-6-[(2-hydroxyethylamino)methyl]-3,4-dihydro-2h-pyran-2-yl]oxy]-2-[(2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| DTXSID001031303 |
| EN300-20605720 |
| (2s)-4-amino-n-[(1r,2s,3s,4r,5s)-5-amino-4-{[(2s,3r)-3-amino-6-{[(2-hydroxyethyl)amino]methyl}-3,4-dihydro-2h-pyran-2-yl]oxy}-2-{[(2r,3r,4r,5r)-3,5-dihydroxy-5-methyl-4-(methylamino)oxan-2-yl]oxy}-3-hydroxycyclohexyl]-2-hydroxybutanamide |
| plazomicinum |
| (2s)-4-amino-n-((1r,2s,3s,4r,5s)-5-amino-4-(((2s,3r)-3-amino-6-(((2-hydroxyethyl)amino)methyl)-3,4-dihydro-2h-pyran-2-yl)oxy)-2-((3-deoxy-4-c-methyl-3-(methylamino)-beta-l-arabinopyranosyl)oxy)-3-hydroxycyclohexyl)-2-hydroxybutanamide |
| zemdri (plazomicin) |
| plazomicina |
| plazomicine |
| j01gb14 |
| AKOS040746239 |
Research Excerpts
Toxicity
| Excerpt | Reference | Relevance |
|---|---|---|
| " Safety was assessed from adverse event (AE) reporting, standard clinical laboratory procedures, and testing for renal, cochlear, and vestibular function." | ( Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Borin, MT; Brooks, CD; Bruss, JB; Cass, RT; Havrilla, NA; Tack, KJ; Young, D, 2011) | 0.37 |
| " The full repertoire of cellular targets and processes leading to the toxicity of aminoglycosides is not fully resolved, making it challenging to devise rational directions to circumvent their adverse effects." | ( The relationship between the structure and toxicity of aminoglycoside antibiotics. Fridman, M; Jospe-Kaufman, M; Siomin, L, 2020) | 0.56 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| " Model-derived pharmacokinetic parameters and safety findings were generally consistent with previously reported plazomicin studies." | ( A Phase 1 Study of Intravenous Plazomicin in Healthy Adults to Assess Potential Effects on the QT/QTc Interval, Safety, and Pharmacokinetics. Choi, T; Gall, J; Gibbons, JA; Riddle, V; Seroogy, J; Van Wart, S, 2019) | 0.51 |
| " A previous population pharmacokinetic (PK) model was used to evaluate the dosage regimen in cUTI patients with different degrees of renal impairment." | ( Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Re Iarikov, D; Jang, SH; Mishra, S; Reynolds, KS; Wu, K; Zhuang, L, 2022) | 0.72 |
Compound-Compound Interactions
| Excerpt | Reference | Relevance |
|---|---|---|
| " Synergy was observed when plazomicin was combined with meropenem, colistin or fosfomycin against both isolates, whilst the combination with tigecycline resulted in indifference." | ( In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains. Culebras, E; Pena, I; Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I, 2015) | 0.42 |
| " To determine synergy with other antibiotics, plazomicin was combined with antibiotics in checkerboard assays against MDR Enterobacteriaceae, including isolates with resistance to aminoglycosides and β-lactams; 10 Escherichia coli isolates, 8 Klebsiella spp." | ( Activity of plazomicin in combination with other antibiotics against multidrug-resistant Enterobacteriaceae. Hall, D; Krause, KM; Marra, A; Pillar, C; Serio, AW; Shinabarger, D; Stoneburner, A; Thwaites, M, 2018) | 0.48 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " The 15-mg/kg dose did not accumulate with repeated dosing over 5 days." | ( Pharmacokinetics and safety of single and multiple doses of ACHN-490 injection administered intravenously in healthy subjects. Borin, MT; Brooks, CD; Bruss, JB; Cass, RT; Havrilla, NA; Tack, KJ; Young, D, 2011) | 0.37 |
| " Due to limited efficacy and safety data, plazomicin is indicated for the treatment of cUTIs in adults with limited or no alternative treatment options, using a dosage regimen of 15 mg/kg intravenously every 24 hours for 4-7 days." | ( Plazomicin: A Next-Generation Aminoglycoside. Chahine, EB; Cho, JC; Piccicacco, N; Shaeer, KM; Zmarlicka, MT, 2019) | 0.51 |
| " A lack of pediatric-specific comparative effectiveness data, uncertain pediatric dosing regimens for several agents, and a relative lack of new antibiotics with pediatric indications approved by the US Food and Drug Administration (FDA) collectively present unique challenges for children." | ( Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children. Chiotos, K; Gerber, JS; Hayes, M; Tamma, PD, 2020) | 0.56 |
| " The objective of this article is to provide the scientific rationales behind the recommended dosage regimen and therapeutic drug monitoring (TDM) of plazomicin in cUTI patients with renal impairment." | ( Application of Population Pharmacokinetic Modeling, Exposure-Response Analysis, and Classification and Regression Tree Analysis to Support Dosage Regimen and Therapeutic Drug Monitoring of Plazomicin in Complicated Urinary Tract Infection Patients with Re Iarikov, D; Jang, SH; Mishra, S; Reynolds, KS; Wu, K; Zhuang, L, 2022) | 0.72 |
| " Yet, selecting an appropriate dose and appropriate time to administer the dose with dosing frequency requires extensive understanding of the interplay between drug pharmacokinetics/pharmacodynamics (PK/PD), the host immune system, and bacterial-resistant mechanisms." | ( Use of pharmacokinetic/pharmacodynamic approaches for dose optimization: a case study of plazomicin. Luterbach, CL; Rao, GG, 2022) | 0.72 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (291)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1329644 | Toxicity in African green monkey 7653 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 50 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329609 | Toxicity in African green monkey 7643 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 16 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329657 | Toxicity in African green monkey B6408 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 6.9 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329665 | Toxicity in African green monkey 7337 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 7.5 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583264 | Antibacterial activity against aminoglycoside-resistant Serratia marcescens expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329454 | Cmax in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329658 | Toxicity in African green monkey B6291 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 12 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329573 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in brain at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1.9 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329553 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in tracheobronchial lymph nodes at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583219 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing ANT(4')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583212 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329560 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in heart at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 2. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329452 | Cmax in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583265 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing ANT(4',4'')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329624 | Toxicity in African green monkey B6408 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 53 IU/ | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329632 | Toxicity in African green monkey 7337 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 67 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329493 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey 8047 model assessed as bacterial burden in lung at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329486 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6672 model assessed as bacterial burden in lung at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329527 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in kidney at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583223 | Antibacterial activity against aminoglycoside-susceptible Acinetobacter baumannii by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID564685 | Antimicrobial activity against multidrug-resistant Klebsiella pneumoniae isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID583221 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(2'') + AAC(6') by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583228 | Antibacterial activity against efflux pump deficient Pseudomonas aeruginosa by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329631 | Toxicity in African green monkey 7643 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 44 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329482 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in lung at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7.7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583237 | Antibacterial activity against Proteus mirabilis by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583250 | Antibacterial activity against aminoglycoside-resistant Serratia liquefaciens expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329537 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in kidney at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583211 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329579 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6861 model assessed as bacterial burden in brain at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583271 | Antibacterial activity against aminoglycoside-resistant Acinetobacter baumannii expressing APH(3')-6 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329663 | Toxicity in African green monkey 8067 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 10 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329554 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6960 model assessed as bacterial burden in tracheobronchial lymph nodes at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583251 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(3)-4 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583236 | Antibacterial activity against Klebsiella spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583255 | Antibacterial activity against aminoglycoside-resistant Enterobacter cloacae expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329574 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in brain at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 1. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329498 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in spleen at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329585 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6436 model assessed as bacterial burden in blood at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329572 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in brain at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1.9 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583235 | Antibacterial activity against Enterobacter spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329494 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6469 model assessed as bacterial burden in spleen at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329481 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in lung at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7.7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329506 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6960 model assessed as bacterial burden in spleen at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583225 | Antibacterial activity against aminoglycoside-resistant Acinetobacter calcoaceticus expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329664 | Toxicity in African green monkey 7643 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 6.1 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583262 | Antibacterial activity against aminoglycoside-resistant Enterobacter cloacae expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329558 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in heart at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2.6 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329592 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in blood at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329634 | Toxicity in African green monkey B5994 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 62 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329477 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey assessed as survival of monkey at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329652 | Toxicity in African green monkey 8067 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 287 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329507 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in spleen at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329534 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in kidney at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329659 | Toxicity in African green monkey B6140 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 6.8 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329580 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2149 model assessed as bacterial burden in brain at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329618 | Toxicity in African green monkey 7929 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 1 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329656 | Toxicity in African green monkey B5994 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 8 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329629 | Toxicity in African green monkey 7929 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 44 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329515 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6415 model assessed as bacterial burden in liver at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329484 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6415 model assessed as bacterial burden in lung at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7.7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329517 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6672 model assessed as bacterial burden in liver at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583226 | Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329650 | Toxicity in African green monkey 7972 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 381 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329555 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in tracheobronchial lymph nodes at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329596 | Toxicity in African green monkey B6127 model infected with Yersinia pestis Colorado 92 assessed as inappetence at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329607 | Toxicity in African green monkey 7929 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 15 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583254 | Antibacterial activity against aminoglycoside-resistant Enterobacter aerogenes expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329551 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6861 model assessed as bacterial burden in tracheobronchial lymph nodes at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329630 | Toxicity in African green monkey 8067 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 40 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329623 | Toxicity in African green monkey B5994 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 35 IU/ | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329522 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6960 model assessed as bacterial burden in liver at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329451 | Cmax in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583230 | Antibacterial activity against Pseudomonas aeruginosa expressing ANT(4')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329503 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6861 model assessed as bacterial burden in spleen at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583261 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329514 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in liver at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 5. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583222 | Antibacterial activity against aminoglycoside-resistant Acinetobacter spp. expressing APH(3')-6 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583243 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(3)-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329508 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey 8047 model assessed as bacterial burden in spleen at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329587 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in blood at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329565 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6861 model assessed as bacterial burden in heart at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329643 | Toxicity in African green monkey 7337 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 55 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329541 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6436 model assessed as bacterial burden in tracheobronchial lymph nodes at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusio | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329569 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in heart at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329616 | Toxicity in African green monkey B6428 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.8 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329582 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6960 model assessed as bacterial burden in brain at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583245 | Antibacterial activity against aminoglycoside-resistant Enterobacter aerogenes expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID564687 | Antimicrobial activity against Escherichia coli ATCC 25922 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID1329615 | Toxicity in African green monkey B6140 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.8 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329475 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey assessed as survival of monkey at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID564688 | Antimicrobial activity against Pseudomonas aeruginosa ATCC 27853 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID1329594 | Toxicity in African green monkey B6127 model infected with Yersinia pestis Colorado 92 assessed as stomach ulcer at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days measured by hematoxylin staining based | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583233 | Antibacterial activity against Citrobacter spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329649 | Toxicity in African green monkey B6428 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 238 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583259 | Antibacterial activity against aminoglycoside-resistant Serratia marcescens expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329476 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey assessed as survival of monkey at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329466 | Clearance in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID564689 | Antimicrobial activity against Klebsiella pneumoniae ATCC 700603 by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID1329602 | Toxicity in African green monkey B6408 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 22 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583238 | Antibacterial activity against indole positive Proteae by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583231 | Antibacterial activity against Pseudomonas aeruginosa expressing AAC(3)-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329581 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in brain at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329488 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6861 model assessed as bacterial burden in lung at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583241 | Antibacterial activity against Acinetobacter spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583232 | Antibacterial activity against Pseudomonas aeruginosa expressing AAC(6')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329511 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in liver at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329548 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in tracheobronchial lymph nodes at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329545 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in tracheobronchial lymph nodes at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusio | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329655 | Toxicity in African green monkey 7653 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 319 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329544 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in tracheobronchial lymph nodes at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusio | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329619 | Toxicity in African green monkey 8067 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.8 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329598 | Toxicity in African green monkey B6127 model infected with Yersinia pestis Colorado 92 assessed as elevation of blood urea nitrogen at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583234 | Antibacterial activity against Escherichia coli by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583218 | Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329566 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2149 model assessed as bacterial burden in heart at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329456 | AUC (0 to 24 hrs) in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329500 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in spleen at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583270 | Antibacterial activity against aminoglycoside-resistant Acinetobacter baumannii expressing ANT(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583249 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583224 | Antibacterial activity against Acinetobacter baumannii ATCC 19606 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329610 | Toxicity in African green monkey 7337 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 15 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329453 | Cmax in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329588 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in blood at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583268 | Antibacterial activity against aminoglycoside-resistant Staphylococcus epidermidis expressing APH(2'') + AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583272 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa expressing AAC(6')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329529 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in kidney at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329611 | Toxicity in African green monkey 7653 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 22 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583242 | Antibacterial activity against Pseudomonas aeruginosa by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329469 | Volume of distribution at steady state in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329646 | Toxicity in African green monkey B6408 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 249 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583269 | Antibacterial activity against aminoglycoside-resistant Acinetobacter baumannii expressing AAC(3')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329513 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in liver at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329559 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in heart at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2.6 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329458 | AUC (0 to 24 hrs) in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329491 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6960 model assessed as bacterial burden in lung at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583208 | Antibacterial activity against Klebsiella pneumoniae ATCC 10031 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329457 | AUC (0 to 24 hrs) in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329540 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey 8047 model assessed as bacterial burden in kidney at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329543 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in tracheobronchial lymph nodes at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329459 | Elimination half life in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329480 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6469 model assessed as bacterial burden in lung at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7.7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329539 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in kidney at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329472 | Toxicity in African green monkey assessed as effect on serum creatinine level at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329461 | Elimination half life in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583267 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(2'') + AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329642 | Toxicity in African green monkey 7643 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 53 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329613 | Toxicity in African green monkey B6408 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.5 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329654 | Toxicity in African green monkey 7337 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 310 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329593 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in blood at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329584 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey 8047 model assessed as bacterial burden in brain at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583266 | Antibacterial activity against aminoglycoside-resistant Staphylococcus epidermidis expressing ANT(4',4'')-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329509 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6436 model assessed as bacterial burden in liver at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329620 | Toxicity in African green monkey 7643 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.5 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329519 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6861 model assessed as bacterial burden in liver at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329479 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6436 model assessed as bacterial burden in lung at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7.7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583210 | Antibacterial activity against Escherichia coli ATCC 25922 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583429 | Antibacterial activity against aminoglycoside-resistant Staphylococcus epidermidis expressing APH(3')-3 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329464 | Clearance in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329635 | Toxicity in African green monkey B6408 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 109 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583258 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329621 | Toxicity in African green monkey 7337 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.7 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329530 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in kidney at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329639 | Toxicity in African green monkey 7972 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 30 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329578 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in brain at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583252 | Antibacterial activity against aminoglycoside-resistant Klebsiella pneumoniae expressing AAC(3)-4 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329526 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6469 model assessed as bacterial burden in kidney at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329627 | Toxicity in African green monkey B6428 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 31 IU/ | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329570 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey 8047 model assessed as bacterial burden in heart at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583216 | Antibacterial activity against aminoglycoside-resistant Providencia stuartii expressing ANT(2')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329467 | Volume of distribution at steady state in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329628 | Toxicity in African green monkey 7972 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 46 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329495 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in spleen at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329638 | Toxicity in African green monkey B6428 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 83 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329647 | Toxicity in African green monkey B6291 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 212 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329518 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in liver at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329504 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2149 model assessed as bacterial burden in spleen at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329563 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6672 model assessed as bacterial burden in heart at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329531 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6415 model assessed as bacterial burden in kidney at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329661 | Toxicity in African green monkey 7972 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 6.9 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329564 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in heart at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329520 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2149 model assessed as bacterial burden in liver at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329567 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in heart at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329533 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6672 model assessed as bacterial burden in kidney at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583273 | Antibacterial activity against aminoglycoside-resistant Pseudomonas aeruginosa expressing ANT(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329591 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in blood at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329550 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in tracheobronchial lymph nodes at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583248 | Antibacterial activity against aminoglycoside-resistant Klebsiella oxytoca expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583244 | Antibacterial activity against aminoglycoside-resistant Citrobacter freundii expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329474 | Toxicity in African green monkey assessed as effect on serum creatinine level at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329523 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in liver at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329465 | Clearance in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329521 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in liver at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583240 | Antibacterial activity against Staphylococcus spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329606 | Toxicity in African green monkey 7972 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 13 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329547 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6415 model assessed as bacterial burden in tracheobronchial lymph nodes at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusio | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583257 | Antibacterial activity against aminoglycoside-resistant Klebsiella oxytoca expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329455 | AUC (0 to 24 hrs) in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329542 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6469 model assessed as bacterial burden in tracheobronchial lymph nodes at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusio | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583214 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3)-4a by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1662708 | Nephrotoxicity in human patients assessed as proportion of patients with higher serum creatinine level | 2020 | Bioorganic & medicinal chemistry letters, 07-01, Volume: 30, Issue:13 | The relationship between the structure and toxicity of aminoglycoside antibiotics. |
| AID1329492 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in lung at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583209 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583213 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing ANT(3')-1b by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329589 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in blood at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 1. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329608 | Toxicity in African green monkey 8067 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 13 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329597 | Toxicity in African green monkey B6127 model infected with Yersinia pestis Colorado 92 assessed as dehydration at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583217 | Antibacterial activity against aminoglycoside-resistant Serratia marcescens expressing ANT(2''), AAC(6') by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329590 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in blood at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329501 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6672 model assessed as bacterial burden in spleen at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329525 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6436 model assessed as bacterial burden in kidney at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID564686 | Antimicrobial activity against beta lactamase KPC-producing Klebsiella pneumoniae isolates by microdilution method | 2009 | Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10 | ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. |
| AID583256 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329571 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in brain at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329586 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in blood at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329502 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in spleen at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329636 | Toxicity in African green monkey B6291 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 47 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329568 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6960 model assessed as bacterial burden in heart at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329612 | Toxicity in African green monkey B5994 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.6 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583260 | Antibacterial activity against aminoglycoside-resistant Enterobacter gergoviae expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329528 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in kidney at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329641 | Toxicity in African green monkey 8067 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 45 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329546 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in tracheobronchial lymph nodes at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusio | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329470 | Volume of distribution at steady state in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329512 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in liver at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329645 | Toxicity in African green monkey B5994 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 364 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329496 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6106 model assessed as bacterial burden in spleen at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329599 | Toxicity in African green monkey B6127 model infected with Yersinia pestis Colorado 92 assessed as effect on serum electrolyte abnormality at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329576 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in brain at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329603 | Toxicity in African green monkey B6291 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 24 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583229 | Antibacterial activity against Pseudomonas aeruginosa expressing mexXY operon by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329473 | Toxicity in African green monkey assessed as effect on serum creatinine level at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329557 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in heart at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329460 | Elimination half life in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329625 | Toxicity in African green monkey B6291 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 77 IU/ | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329660 | Toxicity in African green monkey B6428 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 6.2 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329490 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in lung at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329617 | Toxicity in African green monkey 7972 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.8 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329651 | Toxicity in African green monkey 7929 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 653 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329549 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6672 model assessed as bacterial burden in tracheobronchial lymph nodes at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329662 | Toxicity in African green monkey 7929 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 10.9 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329604 | Toxicity in African green monkey B6140 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 24 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329478 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey assessed as improvement in survival of monkey at 6.25 to 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329600 | Toxicity in African green monkey B6127 model infected with Yersinia pestis Colorado 92 assessed as tubule damage at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days by hematoxylin staining based assay | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329633 | Toxicity in African green monkey 7653 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 37 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329640 | Toxicity in African green monkey 7929 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 63 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329626 | Toxicity in African green monkey B6140 model infected with Yersinia pestis Colorado 92 assessed as serum gamma glutamyl-transferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 55 IU/ | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329524 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey 8047 model assessed as bacterial burden in liver at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329485 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in lung at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583215 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing armA methylase by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329510 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6469 model assessed as bacterial burden in liver at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5.2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583247 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329637 | Toxicity in African green monkey B6140 model infected with Yersinia pestis Colorado 92 assessed as serum alanine aminotransferase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 180 IU/L | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329552 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2149 model assessed as bacterial burden in tracheobronchial lymph nodes at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infus | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329601 | Toxicity in African green monkey B5994 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 15 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329449 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6873 model assessed as bacterial burden in lung at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329535 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6861 model assessed as bacterial burden in kidney at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583227 | Antibacterial activity against wild type Pseudomonas aeruginosa expressing efflux pump by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329532 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in kidney at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583239 | Antibacterial activity against Serratia spp. by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583246 | Antibacterial activity against aminoglycoside-resistant Enterobacter cloacae expressing AAC(3)-2 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID583253 | Antibacterial activity against aminoglycoside-resistant Citrobacter freundii expressing AAC(6')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329575 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6415 model assessed as bacterial burden in brain at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1.9 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329471 | Toxicity in African green monkey assessed as effect on serum creatinine level at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329653 | Toxicity in African green monkey 7643 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 278 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329648 | Toxicity in African green monkey B6140 model infected with Yersinia pestis Colorado 92 assessed as serum lactate dehydrogenase level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 290 IU/L) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329622 | Toxicity in African green monkey 7653 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.6 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329463 | Clearance in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 1 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329595 | Toxicity in African green monkey B6127 model infected with Yersinia pestis Colorado 92 assessed as weight loss at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days measured from day 7 to 14 post dose | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329462 | Elimination half life in African green monkey blood at 35 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329556 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey 8047 model assessed as bacterial burden in tracheobronchial lymph nodes at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusi | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329536 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2149 model assessed as bacterial burden in kidney at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329499 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6415 model assessed as bacterial burden in spleen at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329666 | Toxicity in African green monkey 7653 model infected with Yersinia pestis Colorado 92 assessed as total white blood cell count at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 7.5 10'3/microL) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329562 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in heart at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329583 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6988 model assessed as bacterial burden in brain at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583263 | Antibacterial activity against aminoglycoside-resistant Escherichia coli expressing AAC(2'')-1 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329468 | Volume of distribution at steady state in African green monkey blood at 25 mg/kg administered as iv infusion twice daily for 7 consecutive days measured on day 7 by LC-MS/MS analysis | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329605 | Toxicity in African green monkey B6428 model infected with Yersinia pestis Colorado 92 assessed as blood urea nitrogen level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 16 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329505 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6889 model assessed as bacterial burden in spleen at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329489 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2149 model assessed as bacterial burden in lung at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329516 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey C2083 model assessed as bacterial burden in liver at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 5 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329538 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6960 model assessed as bacterial burden in kidney at 6.25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329614 | Toxicity in African green monkey B6291 model infected with Yersinia pestis Colorado 92 assessed as serum creatinine level at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 0.6 mg/dl) | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329483 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6127 model assessed as bacterial burden in lung at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 10 days (Rvb = 7.7 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID583220 | Antibacterial activity against aminoglycoside-resistant Staphylococcus aureus expressing APH(3')-3 by broth microdilution method | 2010 | Antimicrobial agents and chemotherapy, Nov, Volume: 54, Issue:11 | Synthesis and spectrum of the neoglycoside ACHN-490. |
| AID1329450 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6436 model assessed as bacterial burden in spleen at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329577 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6672 model assessed as bacterial burden in brain at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329487 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6783 model assessed as bacterial burden in lung at 12.5 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 7. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329561 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6415 model assessed as bacterial burden in heart at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 2.6 | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| AID1329497 | Antibacterial activity against Yersinia pestis Colorado 92 infected in African green monkey B6872 model assessed as bacterial burden in spleen at 25 mg/kg, iv administered within 6 hrs post onset of sustained fever as 30 mins infusion for 5 days (Rvb = 1. | 2016 | Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24 | Plazomicin is effective in a non-human primate pneumonic plague model. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (80)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.25) | 29.6817 |
| 2010's | 51 (63.75) | 24.3611 |
| 2020's | 28 (35.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 16.50
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (16.50) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 7 (8.43%) | 5.53% |
| Reviews | 17 (20.48%) | 6.00% |
| Case Studies | 1 (1.20%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 58 (69.88%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||